Literature DB >> 33283624

Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis.

Charles-Antoine Assenmacher1, Sara F Santagostino2, Mark A Oyama3,4, Jean-Christophe Marine5, Elise Bonvin6, Enrico Radaelli1.   

Abstract

The mouse line carrying the Tg(Tyr-NRAS*Q61K)1Bee transgene is widely used to model in vivo NRAS-driven melanomagenesis. Although the pathological features of this model are well described, classification and interpretation of the resulting proliferative lesions-including their origin, evolution, grading, and pathobiological significance-are still unclear and not supported by molecular and biological evidence. Focusing on their classification and grading, this work combines histopathology and expression analysis (using both immunohistochemistry [IHC] and quantitative PCR) of selected biomarkers to study the full spectrum of cutaneous and lymph nodal melanocytic proliferations in the Tg(Tyr-NRAS*Q61K)1Bee mouse. The analysis of cutaneous and lymph nodal melanocytic proliferations has demonstrated that a linear correlation exists between tumor grade and Ki-67, microphthalmia-associated transcription factor (MITF), gp100, and nestin IHC, with a significantly increased expression in high-grade lesions compared with low-grade lesions. The accuracy of the assessment of MITF IHC in melanomas was also confirmed by quantitative PCR analysis. In conclusion, we believe the incorporation of MITF, Ki-67, gp100, and nestin analysis into the histopathological classification/grading scheme of melanocytic proliferations described for this model will help to assess with accuracy the nature and evolution of the phenotype, monitor disease progression, and predict response to experimental treatment or other preclinical manipulations.

Entities:  

Keywords:  NRAS; immunohistochemistry; lymph nodes; melanoma; mice; skin

Mesh:

Substances:

Year:  2020        PMID: 33283624      PMCID: PMC7905489          DOI: 10.1369/0022155420977970

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  71 in total

1.  Expression of oncogenic BRAFV600E in melanocytes induces Schwannian differentiation in vivo.

Authors:  Chi Luo; Jodie R Pietruska; Jinghao Sheng; Roderick T Bronson; Miaofen G Hu; Rutao Cui; Philip W Hinds
Journal:  Pigment Cell Melanoma Res       Date:  2015-06-20       Impact factor: 4.693

2.  Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas.

Authors:  Marc Gillard; Edouard Cadieu; Clotilde De Brito; Jérôme Abadie; Béatrice Vergier; Patrick Devauchelle; Frédérique Degorce; Stephane Dréano; Aline Primot; Laetitia Dorso; Marie Lagadic; Francis Galibert; Benoit Hédan; Marie-Dominique Galibert; Catherine André
Journal:  Pigment Cell Melanoma Res       Date:  2013-11-01       Impact factor: 4.693

3.  PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.

Authors:  S Roels; K Tilmant; R Ducatelle
Journal:  J Comp Pathol       Date:  1999-07       Impact factor: 1.311

4.  Malignant melanoma primary in lymph node. The case of the missing link.

Authors:  B V Shenoy; L Fort; S P Benjamin
Journal:  Am J Surg Pathol       Date:  1987-02       Impact factor: 6.394

5.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

6.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson
Journal:  CA Cancer J Clin       Date:  2017-10-13       Impact factor: 508.702

7.  A role for ATF2 in regulating MITF and melanoma development.

Authors:  Meera Shah; Anindita Bhoumik; Vikas Goel; Antimone Dewing; Wolfgang Breitwieser; Harriet Kluger; Stan Krajewski; Maryla Krajewska; Jason Dehart; Eric Lau; David M Kallenberg; Hyeongnam Jeong; Alexey Eroshkin; Dorothy C Bennett; Lynda Chin; Marcus Bosenberg; Nic Jones; Ze'ev A Ronai
Journal:  PLoS Genet       Date:  2010-12-23       Impact factor: 5.917

Review 8.  Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity.

Authors:  Niels Vandamme; Geert Berx
Journal:  Front Oncol       Date:  2014-12-09       Impact factor: 6.244

Review 9.  MITF in melanoma: mechanisms behind its expression and activity.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  Cell Mol Life Sci       Date:  2014-11-30       Impact factor: 9.261

Review 10.  NRAS-mutant melanoma: current challenges and future prospect.

Authors:  Eva Muñoz-Couselo; Ester Zamora Adelantado; Carolina Ortiz; Jesús Soberino García; José Perez-Garcia
Journal:  Onco Targets Ther       Date:  2017-08-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.